- Conditions
- Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome
- Interventions
- VCL-CB01, Phosphate-buffered Saline (PBS)
- Biological · Other
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Duarte, California • Denver, Colorado + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1345–1368
of 9,145
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- bortezomib
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Madison, Wisconsin
- Conditions
- Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Interventions
- tivozanib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Rochester, Minnesota + 2 more
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer
- Interventions
- Bevacizumab, Cisplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration, Topotecan Hydrochloride
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 541
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 351 more
- Conditions
- Immune System Disorder
- Interventions
- Isatuximab SAR650984, Acetaminophen (paracetamol) or equivalent, Ranitidine or equivalent, Diphenhydramine or equivalent, Methylprednisolone or equivalent, Montelukast or equivalent
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- San Francisco, California • Rochester, Minnesota • New York, New York + 1 more
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
- Interventions
- Dasatinib, Imatinib Mesylate, Laboratory Biomarker Analysis, Nilotinib, Pembrolizumab
- Drug · Other · Biological
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2031
- U.S. locations
- 291
- States / cities
- Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 209 more
- Conditions
- Spinal Cord Injuries, Blood Pressure Disorders
- Interventions
- ARC-IM System Implantation, ARC-IM Therapy (Group 1), ARC-IM Therapy (Group 2)
- Procedure · Device
- Lead sponsor
- ONWARD Medical, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Englewood, Colorado • Miami, Florida + 8 more
- Conditions
- Epilepsy
- Interventions
- Neuro Ablation - Functional
- Device
- Lead sponsor
- InSightec
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 4
- States / cities
- Stanford, California • Kansas City, Kansas • Rochester, Minnesota + 1 more
- Conditions
- Hyperlipidemia, Dyslipidemia
- Interventions
- torcetrapib/atorvastatin, ezetimibe/simvastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,784 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 123
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more
- Conditions
- Eating Disorder, Emotional Disorder
- Interventions
- Integrative cognitive-affective therapy for adolescents (ICAT-A)
- Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 14 Years to 20 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm
- Interventions
- Arsenic Trioxide, Cytarabine, Diagnostic Laboratory Biomarker Analysis, Idarubicin, Mercaptopurine, Methotrexate, Mitoxantrone Hydrochloride, Tretinoin
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2022
- U.S. locations
- 112
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 87 more
- Conditions
- Aortic Stenosis, Severe
- Interventions
- SAPIEN X4 THV, SAPIEN X4S
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2037
- U.S. locations
- 58
- States / cities
- La Jolla, California • Los Angeles, California • Newport Beach, California + 44 more
- Conditions
- Aortic Aneurysm, Abdominal
- Interventions
- IMPEDE-FX RapidFill Implants, EndoVascular Aneurysm Repair
- Device · Procedure
- Lead sponsor
- Shape Memory Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 32 more
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Etoposide, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 503 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 22
- States / cities
- Fort Myers, Florida • Orlando, Florida • St. Petersburg, Florida + 18 more
- Conditions
- Tetralogy of Fallot, Congenital Heart Disease
- Interventions
- Remote Heart Rhythm Monitoring
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pamrevlumab, Placebo
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • San Francisco, California • Denver, Colorado + 20 more
- Conditions
- Pleural Mesothelial Neoplasm
- Interventions
- Immunotherapy, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Other · Radiation
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 1,673 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 928
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 580 more
- Conditions
- Lymphoma
- Interventions
- rituximab
- Biological
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 17 more
- Conditions
- Cardiac Amyloidosis
- Interventions
- AI ECG Amyloid algorithm
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more
- Conditions
- Post-ect Agitation, Post-ictal Agitation
- Interventions
- Weighted blanket, Usual Care Group
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Afatinib Dimaleate, Cetuximab, Laboratory Biomarker Analysis
- Drug · Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 638
- States / cities
- Fort Smith, Arkansas • Hot Springs, Arkansas • Jonesboro, Arkansas + 406 more
- Conditions
- Anaplastic Thyroid Cancer, Recurrent Thyroid Cancer
- Interventions
- efatutazone, paclitaxel
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 253
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 168 more
- Conditions
- Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Cholangiocarcinoma, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- Carboplatin, Paclitaxel, Pevonedistat
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 419
- States / cities
- Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 254 more